Moneycontrol PRO
LAMF
LAMF

Dr Reddys Laboratories Shares Rise in Today's Trading Session

With a marginal increase in share price and a Very Bullish market sentiment, Dr Reddys Laboratories continues to be a key player in the pharmaceutical sector.
June 04, 2025 / 11:16 IST
Disclaimer This is an AI-assisted live blog with updates from multiple sources Disclaimer

During today's trading session, Dr Reddys Laboratories experienced a marginal increase, with its shares rising by 0.56% to Rs 1,255.30. This movement reflects ongoing market activity for the pharmaceutical giant, which is a component of the NIFTY 50 STOCKS index.

Financial Performance Overview

Recent financial data provides insights into Dr Reddys Laboratories' performance. All figures are consolidated.

Revenue Trends:

  • Mar 2024: Rs 7,113.80 Cr
  • Jun 2024: Rs 7,696.10 Cr
  • Sep 2024: Rs 8,038.20 Cr
  • Dec 2024: Rs 8,381.20 Cr
  • Mar 2025: Rs 8,528.40 Cr

The company has demonstrated consistent revenue growth over the past year, with revenues climbing steadily each quarter.

Net Profit:

  • Mar 2024: Rs 1,306.30 Cr
  • Jun 2024: Rs 1,386.50 Cr
  • Sep 2024: Rs 1,335.80 Cr
  • Dec 2024: Rs 1,400.00 Cr
  • Mar 2025: Rs 1,581.20 Cr

Net profit figures also reveal a positive trajectory, with a notable increase in the most recent quarter.

Earnings Per Share (EPS):

  • Mar 2024: Rs 78.66
  • Jun 2024: Rs 83.61
  • Sep 2024: Rs 80.45
  • Dec 2024: Rs 16.97
  • Mar 2025: Rs 19.12

The EPS figures show some fluctuation, with a significant drop in December 2024 followed by a recovery in March 2025.

Annual Financial Highlights:

Looking at the annual data, Dr Reddys Laboratories has shown substantial growth over the past five years.

Key Figures:

YearRevenue (Cr)Net Profit (Cr)EPSBVPSROEDebt to Equity
202119,047.501,903.60117.671,060.2011.060.15
202221,545.202,112.20131.571,154.5911.350.16
202324,669.704,470.30271.471,397.7319.350.05
202428,011.105,563.20335.221,693.9319.740.06
202532,643.905,703.5064.22402.2716.850.12

From 2021 to 2025, Dr Reddys Laboratories has consistently increased its revenue and net profit, reflecting strong financial health. However, EPS saw a drop in 2025. The Debt to Equity ratio remains well-managed, indicating a stable financial structure.

Market Sentiment

According to Moneycontrol analysis, the market sentiment for Dr Reddys Laboratories is Very Bullish as of June 4, 2025.

With an increase in share price and a Very Bullish market sentiment, Dr Reddys Laboratories continues to be a key player in the pharmaceutical sector.

Alpha Desk
first published: Jun 4, 2025 11:16 am

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347